Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-8e9729f37593f28a655449a0b1bb5596"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-8e9729f37593f28a655449a0b1bb5596"/>
<resource>
<Composition>
<id value="composition-en-8e9729f37593f28a655449a0b1bb5596"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-8e9729f37593f28a655449a0b1bb5596"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-8e9729f37593f28a655449a0b1bb5596</b></p><a name="composition-en-8e9729f37593f28a655449a0b1bb5596"> </a><a name="hccomposition-en-8e9729f37593f28a655449a0b1bb5596"> </a><a name="composition-en-8e9729f37593f28a655449a0b1bb5596-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/204/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - trisenox</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/204/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp8e9729f37593f28a655449a0b1bb5596"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - trisenox"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What TRISENOX is and what it is used for</li><li>What you need to know before you are given TRISENOX</li><li>How TRISENOX is given</li><li>Possible side effects</li><li>How to store TRISENOX</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What trisenox is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What trisenox is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>TRISENOX is used in adult patients with newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL), and in adult patients, whose disease has not responded to other therapies. APL is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take trisenox"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take trisenox"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>TRISENOX must be given under the supervision of a physician experienced in the treatment of acute leukaemias.</p><p>You must not receive TRISENOX If you are allergic to arsenic trioxide or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions You must talk to your doctor or nurse before you are given TRISENOX, if</p><ul><li>you have impaired kidney function.</li><li>you have any liver problems.</li></ul><p>Your doctor will take the following precautions:</p><ul><li>Tests will be performed to check the amount of potassium, magnesium, calcium and creatinine in your blood before your first dose of TRISENOX.</li><li>You should have an electrical recording of the heart (electrocardiogram ECG) performed before your first dose.</li><li>Blood tests (potassium, calcium, magnesium and liver function) should be repeated during your treatment with TRISENOX.</li><li>In addition, you will receive electrocardiograms twice weekly.</li><li>If you are at risk for a certain type of abnormal heart rhythm (e.g. torsade de pointes or QTc prolongation), your heart will be monitored continuously.</li><li>Your doctor may monitor your health during and after treatment, since arsenic trioxide, the active substance in TRISENOX, may cause other cancers. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.</li><li>Follow-up of your cognitive and mobility functions if you are at risk for vitamin B1 deficiency.</li></ul><p>Children and adolescents TRISENOX is not recommended in children and adolescents below 18 years of age.</p><p>Other medicines and TRISENOX Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>In particular tell your doctor</p><ul><li>if you are taking any of various types of medicines which could cause a change in the rhythm of your heartbeat. These include:</li></ul><ul><li>some types of antiarrhythmics (medicines used to correct irregular heart beats, e.g. quinidine, amiodarone, sotalol, dofetilide)</li><li>medicines to treat psychosis (loss of contact with reality, e.g. thioridazine)</li><li>medicines for depression (e.g. amitriptyline)</li><li>some types of medicines to treat bacterial infections (e.g. erythromycin and sparfloxacin)</li><li>some medicines to treat allergies such as hay fever, called antihistamines (e.g. terfenadine and astemizole)</li><li>any medicines that cause a decrease in magnesium or potassium in your blood (e.g. amphotericin B)</li><li>cisapride (a medicine used to relieve certain stomach problems).<br/>The effect of these medicines on your heartbeat can be made worse by TRISENOX. You must be sure to tell your doctor about all medicines you are taking.</li></ul><ul><li>if you are taking or have recently taken any medicine which may affect your liver. If you are not sure, show the bottle or pack to your doctor.</li></ul><p>TRISENOX with food and drink There are no restrictions on your food or drink while you are receiving TRISENOX.</p><p>Pregnancy Ask your doctor or pharmacist for advice before taking any medicine.</p><p>TRISENOX may cause harm to the foetus when used by pregnant women.</p><p>If you are able to become pregnant, you must use effective birth control during treatment with TRISENOX and for 6 months following completion of treatment.</p><p>If you are pregnant or you become pregnant during the treatment with TRISENOX, you must ask your doctor for advice.</p><p>Men should also use effective contraception and be advised to not father a child while receiving TRISENOX and for 3 months following completion of treatment.</p><p>Breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.<br/>The arsenic in TRISENOX passes into breast milk.<br/>Because TRISENOX can harm nursing infants, do not breast-feed while on and until two weeks after the last dose of TRISENOX.</p><p>Driving and using machines TRISENOX is expected to have no or negligible influence on your ability to drive and use machines. If you experience discomfort or if you feel unwell after a TRISENOX injection, you should wait until the symptoms go away before driving or using machines.</p><p>TRISENOX contains sodium TRISENOX contains less than 1 mmol sodium (23 mg) per dose. This means that the medicine is essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take trisenox"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take trisenox"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Duration and frequency of treatment</p><p>Patients with newly diagnosed acute promyelocytic leukaemia Your doctor will give you TRISENOX once every day as an infusion. In your first treatment cycle, you may be treated every day up to 60 days at most or until your doctor determines that your disease is better. If your disease responds to TRISENOX, you will be given 4 additional treatment cycles. Each cycle consists of 20 doses given 5 days per week (followed by 2 days interruption) for 4 weeks followed by 4 weeks interruption. Your doctor will decide exactly how long you must continue on therapy with TRISENOX.</p><p>Patients with acute promyelocytic leukaemia, whose disease has not responded to other therapies Your doctor will give you TRISENOX once every day as an infusion. In your first treatment cycle, you may be treated every day up to 50 days at most or until your doctor determines that your disease is better. If your disease responds to TRISENOX, you will be given a second treatment cycle of 25 doses given 5 days per week (followed by 2 days interruption) for 5 weeks. Your doctor will decide exactly how long you must continue on therapy with TRISENOX.</p><p>Method and route of administration</p><p>TRISENOX must be diluted with a solution containing glucose or a solution containing sodium chloride.</p><p>TRISENOX is normally given by a doctor or a nurse. It is given as a drip (infusion) into a vein over 1-2 hours, but the infusion may last longer if side effects like flushing and dizziness occur.</p><p>TRISENOX must not be mixed with, or infused through the same tube with other medicines.</p><p>If your doctor or nurse gives you more TRISENOX than he/she should You may experience convulsions, muscle weakness and confusion. If this happens, treatment with TRISENOX must be stopped immediately and your doctor will treat the arsenic overdose.</p><p>If you have any further question on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor or nurse straight away if you notice the following side effects, as these may be signs of a severe condition called differentiation syndrome , which might be fatal:</p><ul><li>difficulty in breathing</li><li>coughing</li><li>chest pain</li><li>fever</li></ul><p>Tell your doctor or nurse straight away if you notice one or more of the following side effects, as these may be signs of allergic reaction:</p><ul><li>difficulty in breathing</li><li>fever</li><li>sudden weight gain</li><li>water retention</li><li>fainting</li><li>palpitations (strong heartbeat you can feel in your chest)</li></ul><p>While on treatment with TRISENOX, you may experience some of the following reactions:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>fatigue (weariness), pain, fever, headache</li><li>nausea, vomiting, diarrhoea</li><li>dizziness, muscle pain, numbness or tingling</li><li>rash or itching, increased blood sugar, oedema (swelling due to excess fluid)</li><li>shortness of breath, fast heart beat, abnormal ECG heart tracing</li><li>reduced potassium or magnesium in the blood, liver function tests abnormal including presence of excess bilirubin or gamma-glutamyltransferase in the blood</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>reduction in blood cell counts (platelets, red and/or white blood cells), increased white blood cells</li><li>chills, increased weight</li><li>a fever due to an infection and low levels of white blood cells, herpes zoster infection</li><li>chest pain, bleeding in the lung, hypoxia (low oxygen level), collection of fluid around the heart or the lung, low blood pressure, abnormal heart rhythm</li><li>fit, joint or bone pain, inflammation of the blood vessels</li><li>increased sodium or magnesium, ketones in the blood and urine (ketoacidosis), renal function tests abnormal, kidney failure</li><li>stomach (abdominal) ache</li><li>redness of the skin, swollen face, blurred vision</li></ul><p>Not known (frequency cannot be estimated from the available data):</p><ul><li>lung infection, infection in the blood</li><li>inflammation of the lungs which causes chest pain and breathlessness, cardiac failure</li><li>dehydration, confusion</li><li>Cerebral disease (Encephalopathy, Wernicke encephalopathy) with various manifestations including difficulties to use arms and legs, speech disorders and confusion</li></ul><p>Reporting of side effects<br/>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store trisenox"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store trisenox"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the ampoule label and the carton.</p><p>This medicine does not require any special storage conditions.</p><p>After dilution, if not used immediately, storage times and conditions before use are the responsibility of your doctor, pharmacist or nurse and would normally not be longer than 24 hours at 2 to 8 C, unless dilution has taken place in a sterile environment.</p><p>This medicine must not be used if you notice foreign particulate matter or if the solution is discoloured.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What TRISENOX contains</p><ul><li>The active substance is arsenic trioxide. Each ml of concentrate contains 1 mg of arsenic</li></ul><p>trioxide. Each ampoule of 10 ml contains 10 mg of arsenic trioxide.</p><ul><li>The other ingredients are sodium hydroxide, hydrochloric acid and water for injections. See</li></ul><p>section 2 TRISENOX contains sodium .</p><p>What TRISENOX looks like and contents of the pack</p><ul><li>TRISENOX is a concentrate for solution for infusion (sterile concentrate). TRISENOX is</li></ul><p>supplied in glass ampoules as a concentrated, clear, colourless, aqueous solution.</p><ul><li>Each carton contains 10 single-use glass ampoules.</li></ul><p>Marketing Authorisation Holder Teva B.V., Swensweg 5, 2031 GA Haarlem, Netherlands</p><p>Manufacturer Almac Pharma Services Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, United Kingdom</p><p>Almac Pharma Services (Ireland) Limited; Finnabair Industrial Estate, Dundalk, Co. Louth, A91 P9KD, Ireland</p><p>Teva Pharmaceuticals Europe B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands</p><p>This leaflet was last revised in {MM/YYYY}</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp8e9729f37593f28a655449a0b1bb5596"/>
<resource>
<MedicinalProductDefinition>
<id value="mp8e9729f37593f28a655449a0b1bb5596"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp8e9729f37593f28a655449a0b1bb5596"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp8e9729f37593f28a655449a0b1bb5596</b></p><a name="mp8e9729f37593f28a655449a0b1bb5596"> </a><a name="hcmp8e9729f37593f28a655449a0b1bb5596"> </a><a name="mp8e9729f37593f28a655449a0b1bb5596-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/204/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: TRISENOX 1 mg/ml concentrate for solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/204/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="TRISENOX 1 mg/ml concentrate for solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
